Gene-editing startup incubated at Google goes public in $267M IPO

Verve Therapeutics, a cholesterol-targeting, gene-editing startup that’s the first biotech to be incubated by the venture capital arm of Google, has hit the public market in a $267 million IPO — more than twice what it was originally hoping to raise.